A study to evalute iron metabolism by hepcidin-25 in patients on hemodialysis treated with epoetin beta pegol once-monthly or twice--monthly
Not Applicable
- Conditions
- Renal anemia on hemodialysis patients
- Registration Number
- JPRN-UMIN000012910
- Lead Sponsor
- kanazawa medical university medical research institute,Division of Aging Research
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
Not provided
Exclusion Criteria
1.patients who do not accept this study 2.patients who have allergy for ESA 3.patients who have uncontrollable high blood pressure 4.patients with factors that could have a clear impact on hemoglobin concentration, such as infectious diseases, malignant tumors, bleeding of moderate or more 5.women who are pregnant,breastfeeding,possibly pregnant,or not willing to use birth control in the period leading up to the end of the study at the time of obtaining informed consent 6.patients who received red bllod cell transfusion within 3 months before enrollment 7.patients who are judged ineligible by the physician in charge
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method (1) biological parameters of iron metabolism(including Hep-25) (2) ERI(ESA Resistance Index) at endpoint (3) pecentage of maintaing the target Hb level for one year
- Secondary Outcome Measures
Name Time Method